Advice

in the absence of a submission from the holder of the marketing authorisation

ceftazidime/avibactam (Zavicefta®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of the following infections in adults: 

• complicated intra-abdominal Infection (cIAI)
• complicated urinary tract infection (cUTI), including pyelonephritis
• hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
• infections due to aerobic Gram-negative organisms in adult patients with limited treatment options

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice55KB (PDF)

Download

Medicine details

Medicine name:
ceftazidime avibactam (Zavicefta)
SMC ID:
1307/18
Indication:
Treatment of the following infections in adults: • complicated intra-abdominal Infection (cIAI) • complicated urinary tract infection (cUTI), including pyelonephritis • hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) • infections due to aerobic Gram-negative organisms in adult patients with limited treatment options
Pharmaceutical company
Pfizer Ltd
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published
15 January 2018